Page 33 - GPD-3-2

Gene & Protein in Disease Review of CAR-T in ADs

27. Huang R, Li X, He Y, et al. Recent advances in CAR-T cell Rheumatol. 2021;17(9):515-532.
engineering. J Hematol Oncol. 2020;13(1):86.
doi: 10.1038/s41584-021-00668-1
doi: 10.1186/s13045-020-00910-5
39. Yu H, Nagafuchi Y, Fujio K. Clinical and immunological
28. Sterner RC, Sterner RM. CAR-T cell therapy: Current biomarkers for systemic lupus erythematosus. Biomolecules.
limitations and potential strategies. Blood Cancer J. 2021;11(7):928.
2021;11(4):69.
doi: 10.3390/biom11070928
doi: 10.1038/s41408-021-00459-7
40. Basta F, Fasola F, Triantafyllias K, Schwarting A. Systemic
29. Honikel MM, Olejniczak SH. Co-stimulatory receptor lupus erythematosus (SLE) therapy: The old and the new.
signaling in CAR-T cells. Biomolecules. 2022;12(9):1303. Rheumatol Ther. 2020;7(3):433-446.
doi: 10.3390/biom12091303 doi: 10.1007/s40744-020-00212-9
30. López-Cantillo G, Urueña C, Camacho BA, Ramírez- 41. Zhang W, Feng J, Cinquina A, et al. Treatment of systemic
Segura C. CAR-T cell performance: How to improve their lupus erythematosus using BCMA-CD19 compound CAR.
persistence? Front Immunol. 2022;13:878209. Stem Cell Rev Rep. 2021;17(6):2120-2123.
doi: 10.3389/fimmu.2022.878209 doi: 10.1007/s12015-021-10251-6
31. Hu Y, Wang J, Wei G, et al. A retrospective comparison of 42. Mackensen A, Müller F, Mougiakakos D, et al. Anti-CD19
allogenic and autologous chimeric antigen receptor T cell CAR T cell therapy for refractory systemic lupus
therapy targeting CD19 in patients with relapsed/refractory erythematosus. Nat Med. 2022;28(10):2124-2132.
acute lymphoblastic leukemia. Bone Marrow Transplant. doi: 10.1038/s41591-022-02017-5
2019;54(8):1208-1217.
43. Davidson HW, Cepeda JR, Sekhar NS, et al. High-efficiency
doi: 10.1038/s41409-018-0403-2
generation of antigen-specific primary mouse cytotoxic
32. Liu E, Marin D, Banerjee P, et al. Use of CAR-transduced T cells for functional testing in an autoimmune diabetes
natural killer cells in CD19-positive lymphoid tumors. model. J Visual Exp. 2019;(150): 10.3791/59985.
N Engl J Med. 2020;382(6):545-553.
doi:10.3791/59985
doi: 10.1056/NEJMoa1910607
44. Zhang L, Sosinowski T, Cox AR, et al. Chimeric antigen
33. Abreu TR, Fonseca NA, Gonçalves N, Moreira JN. Current receptor (CAR) T cells targeting a pathogenic MHC class II:
challenges and emerging opportunities of CAR-T cell Peptide complex modulate the progression of autoimmune
therapies. J Control Release. 2020;319:246-261. diabetes. J Autoimmun. 2019;96:50-58.
doi: 10.1016/j.jconrel.2019.12.047 doi: 10.1016/j.jaut.2018.08.004
34. Mougiakakos D, Krönke G, Völkl S, et al. CD19-targeted 45. Tenspolde M, Zimmermann K, Weber LC, et al. Regulatory
CAR T cells in refractory systemic lupus erythematosus. T cells engineered with a novel insulin-specific chimeric
N Engl J Med. 2021;385(6):567-569. antigen receptor as a candidate immunotherapy for type 1
diabetes. J Autoimmun. 2019;103:102289.
doi: 10.1056/NEJMc2107725
doi: 10.1016/j.jaut.2019.05.017
35. Oh S, Mao X, Manfredo-Vieira S, et al. Precision targeting
of autoantigen-specific B cells in muscle-specific tyrosine 46. Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with
kinase myasthenia gravis with chimeric autoantibody T cells expressing anti-CD19 chimeric antigen receptors.
receptor T cells. Nat Biotechnol. 2023;41(9):1229-1238. Nat Rev Clin Oncol. 2013;10(5):267-276.
doi: 10.1038/s41587-022-01637-z doi: 10.1038/nrclinonc.2013.46
36. Terskikh AV, Le Doussal JM, Crameri R, Fisch I, Mach JP, 47. Stadinski BD, Zhang L, Crawford F, Marrack P, Eisenbarth
Kajava AV. “Peptabody”: A new type of high avidity binding GS, Kappler JW. Diabetogenic T cells recognize insulin
protein. Proc Natl Acad Sci U S A. 1997;94(5):1663-1668. bound to IAg7 in an unexpected, weakly binding register.
Proc Natl Acad Sci U S A. 2010;107(24):10978-10983.
doi: 10.1073/pnas.94.5.1663
doi: 10.1073/pnas.1006545107
37. Fortuna G, Brennan MT. Systemic lupus erythematosus:
Epidemiology, pathophysiology, manifestations, and 48. Spanier JA, Fung V, Wardell CM, et al. Insulin B peptide-MHC
management. Dent Clin North Am. 2013;57(4):631-655. class II-specific chimeric antigen receptor-Tregs prevent
autoimmune diabetes. bioRxiv. 2023;2023.02.23.529737
doi: 10.1016/j.cden.2013.06.003
doi: 10.1101/2023.02.23.529737
38. Barber MRW, Drenkard C, Falasinnu T, et al. Global
epidemiology of systemic lupus erythematosus. Nat Rev 49. Melchionda V, Harman KE. Pemphigus vulgaris and

Volume 3 Issue 2 (2024) 12 doi: 10.36922/gpd.2851